1.770SEK+38.71%Mkt Cap: 643.76M SEKP/E: —Last update: 2026-05-13
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-2.38
PEG—
P/B-7.82
P/S9.05
EV/EBITDA-2.42
EV/Revenue7.59
EPS (TTM)-1.04
EPS (Forward)-0.71
Cash Flow & Leverage
FCF Yield-21.51%
FCF Margin-194.73%
Operating CF-222.88M SEK
CapEx (TTM)—
Net Debt/EBITDA-0.26
Net Debt57.13M SEK
Technical
SMA 501.428 (+23.9%)
SMA 2003.695 (-52.1%)
Beta-1.42
S&P 52W Chg24.23%
Avg Vol (30d)5.84M
Avg Vol (10d)10.06M
Technical Indicators
RSI (14)71.7
MACD-0.0253
MACD Signal-0.0668
MACD Hist.+0.0415
BB Upper1.572 SEK
BB Middle1.353 SEK
BB Lower1.135 SEK
BB Width32.29%
ATR (14)0.1489 SEK
Vol Ratio (20d)7.89x
52W Range
1.2659% of range6.960
52W High6.960 SEK
52W Low1.265 SEK
Profitability
Gross Margin96.55%
EBITDA Margin0.00%
Profit Margin-350.94%
Oper. Margin-336.71%
ROE423.81%
ROA-184.33%
Revenue Growth87.30%
Earnings Growth—
Balance Sheet
Debt/Equity-2.37
Current Ratio2.61
Quick Ratio2.19
Book Value/Sh-0.2160 SEK
Cash/Share0.3020 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.381.15M
Float261.70M
Insiders9.05%
Institutions9.32%
Analyst Consensus
Rating—
Target (Mean)2.800 SEK
Target Range2.800 SEK – 2.800 SEK
# Analysts1
Company
Market Cap643.76M SEK
Enterprise Value539.82M SEK
Revenue (TTM)71.12M SEK
Gross Profit68.67M SEK
Net Income (TTM)-249.59M SEK
Revenue/Share0.3130 SEK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees75
Last Price1.770 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0009414576